Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Holdings Raised by Auxier Asset Management

Auxier Asset Management increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 61,503 shares of the medical equipment provider’s stock after purchasing an additional 543 shares during the quarter. Auxier Asset Management’s holdings in Zimmer Biomet were worth $6,675,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. TD Asset Management Inc lifted its position in shares of Zimmer Biomet by 10.1% in the 4th quarter. TD Asset Management Inc now owns 169,595 shares of the medical equipment provider’s stock worth $20,640,000 after buying an additional 15,552 shares during the last quarter. Bank of Nova Scotia lifted its holdings in Zimmer Biomet by 499.0% in the fourth quarter. Bank of Nova Scotia now owns 134,729 shares of the medical equipment provider’s stock worth $16,397,000 after acquiring an additional 112,237 shares during the last quarter. Speece Thorson Capital Group Inc. boosted its stake in Zimmer Biomet by 13.8% in the fourth quarter. Speece Thorson Capital Group Inc. now owns 158,202 shares of the medical equipment provider’s stock valued at $19,253,000 after acquiring an additional 19,144 shares during the period. APG Asset Management US Inc. bought a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $14,530,000. Finally, M&G Plc acquired a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $7,397,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ZBH shares. Citigroup reduced their price objective on Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. TD Cowen lowered their price target on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research report on Friday, September 6th. Wolfe Research initiated coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Raymond James reduced their target price on shares of Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Finally, Oppenheimer dropped their price target on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and an average target price of $125.17.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $106.42 on Friday. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $133.90. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31. The firm has a 50-day moving average of $109.83 and a two-hundred day moving average of $115.52. The company has a market capitalization of $21.67 billion, a price-to-earnings ratio of 23.03, a PEG ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, beating the consensus estimate of $1.99 by $0.02. The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.82 earnings per share. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.02 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.